Topics:

Novartis probes controversy around Diovan studies

Tools

Novartis ($NVS) has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant. It's the latest in a widening controversy over studies of the big-market drug, including retracted papers co-authored by former Kyoto Prefectural University researcher Hiroaki Matsubaba. But now one of Novartis' own employees has been ensnared in the controversy, Forbes reported. Article

Filed Under